Actively Recruiting
The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
Led by The First Affiliated Hospital of University of South China · Updated on 2025-08-29
800
Participants Needed
1
Research Sites
150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatocellular carcinoma (HCC) is a globally prevalent malignancy. In its characteristic "chronic hepatitis-liver cirrhosis-HCC" progression trilogy, patients with cirrhosis demonstrate a 5-year HCC incidence rate of 3%-5%, yet effective monitoring strategies remain lacking. Current early diagnosis relies on the combination of imaging techniques and serum alpha-fetoprotein (AFP), but AFP measurements are frequently confounded by pregnancy and liver diseases, resulting in suboptimal sensitivity and specificity. In recent years, novel tumor biomarkers such as AKR1B10 (Aldo-keto reductase family 1 member B10) have been examined. This multicenter prospective cohort study aims to validate the predictive value of serum AKR1B10 for malignant transformation in cirrhosis-HCC progression, and evaluate its combined efficacy with existing risk prediction models, ultimately establishing a high-sensitivity early diagnostic strategy for clinical implementation.
CONDITIONS
Official Title
The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meets diagnostic criteria for liver cirrhosis and chronic hepatitis
- Aged 18 to 75 years, any gender
- Willing to participate and provides signed informed consent
- Has not participated in other clinical trials within the last 3 months
You will not qualify if you...
- Pregnant or breastfeeding
- Incomplete clinical, serological, or imaging data
- Lost to follow-up before study endpoints
- Younger than 18 years or older than 75 years
- Severe systemic diseases affecting cardiovascular, cerebral, pulmonary, renal, or blood systems
- Current or recent (within 3 months) participation in other clinical trials
- Diagnosed with hepatocellular carcinoma (HCC)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of South China
Hengyang, Hunan, China, 421001
Actively Recruiting
Research Team
X
Xi Zeng, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here